Provided by Tiger Trade Technology Pte. Ltd.

Regenxbio

7.43
+0.01000.13%
Post-market: 7.430.00000.00%16:59 EDT
Volume:1.04M
Turnover:7.71M
Market Cap:490.48M
PE:-1.97
High:7.62
Open:7.58
Low:7.36
Close:7.42
52wk High:16.19
52wk Low:5.46
Shares:66.01M
Float Shares:57.34M
Volume Ratio:0.63
T/O Rate:1.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7652
EPS(LYR):-3.7593
ROE:-137.63%
ROA:-21.20%
PB:6.83
PE(LYR):-1.98

Loading ...

Regenxbio - Offering Expected to Close on July 20, 2026

THOMSON REUTERS
·
Jul 17

Regenxbio - Prices Public Offering of 10 Mln Shares at $9 and 1.11 Mln Pre-funded Warrants at $9

THOMSON REUTERS
·
Jul 17

Regenxbio - Expects Gross Proceeds of About $100 Mln from Offering

THOMSON REUTERS
·
Jul 17

Stocks to Watch: Netflix, Spacex, Alcoa, Regenxbio

Dow Jones
·
Jul 17

Regenxbio Slides on Plan to Offer $100M of Stock

Dow Jones
·
Jul 17

Regenxbio Shares Down 16.7% After the Bell; Announces Proposed $100 Mln Common Stock Public Offering

THOMSON REUTERS
·
Jul 17

REGENXBIO Announces Proposed $100 Million Public Stock Offering

MT Newswires Live
·
Jul 17

Regenxbio announces $100M common stock offering

TIPRANKS
·
Jul 17

Regenxbio Plans USD 100 Million Common Stock Offering to Raise Capital

Reuters
·
Jul 17

Regenxbio Announces Proposed Public Offering of Common Stock

THOMSON REUTERS
·
Jul 17

Regenxbio CMO Steve Pakola Sells 2,161 Shares Worth $29,479.04

Reuters
·
Jul 07

Regenxbio Chief Medical Officer Steve Pakola Sells USD 695,992 of Common Shares

Reuters
·
Jul 02

Regenxbio Shares Rise on $100M Milestone Payment After First Patient Dosed in Eye-disease Trial

Dow Jones
·
Jul 02

Regenxbio Rises on $100 Million Abbvie Milestone for Eye Disease Drug

Reuters
·
Jun 29

Regenxbio Doses First Patient in Phase Iib/iii Naavigate Trial of Sura-vec for Diabetic Retinopathy, Triggers $100 Million Abbvie Milestone

Reuters
·
Jun 29

Regenxbio - to Announce Topline Data from Atmosphere and Ascent Trials of Sura-vec in Q4 2026

THOMSON REUTERS
·
Jun 29

Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX), Cronos Group (CRON) and Boston Scientific (BSX)

TIPRANKS
·
Jun 25

Regenxbio Price Target Maintained with a $26.00/share by HC Wainwright & Co.

Dow Jones
·
Jun 25

Regenxbio completes dosing in confirmatory study of RGX-202

TIPRANKS
·
Jun 24

Regenxbio - Completes Dosing in Rgx-202 Confirmatory Study

THOMSON REUTERS
·
Jun 24